Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis.

New England Journal of Medicine, 2015

1,870 citations recorded by the source corpus.

Subfields: Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/f2f14b9fa6bb72a35819fae3db727b800e1b968a

Citations in the corpus

• Diagnostic criteria for idiopathic pulmonary fibrosis: a Fleischner Society White Paper. (2017, neutral): “3,12–17 A substantial proportion of patients with interstitial pneumonia with autoimmune features have imaging or pathological features of usual interstitial pneumonia (UIP), 18 and have similar survival to patients with IPF.”
• Ten years of anti-vascular endothelial growth factor therapy (2016, background): “Nindedanib also resulted in clinical improvement in patients with idiopathic pulmonary fibrosis, a fatal non-neoplastic lung disease in which VEGFRs, PDGFRs and FGFRs have been implicated 134 , gaining FDA and EMA approval for this indication.”
• Acute Exacerbation of Idiopathic Pulmonary Fibrosis. An International Working Group Report. (2016, critical): “supported but not confirmed by the 1066-subject phase 3 program (15).”
• An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline. (2015, methodology): “treatment in patients with IPF was evaluated in three RCTs published in two separate reports (29, 30).”